IMMUNIC IMUX 深 沪
等待开盘 03-26 09:30:00 美东时间
1.32
+0.070
+5.60%
华盛通- 最 高1.35
- 今 开1.26
- 成交量 199.45万股
- 最 低 1.26
- 昨 收 1.25
- 总市值 1.72亿
- 52周最高 1.51
- 市盈率 静 --
- 换手率 1.53%
- 52周最低 0.5062
- 委 比 -57.86%
- 总股本 1.30亿
- 历史最高 28.99
- 量 比 1.11
- 振 幅 7.20%
- 历史最低 0.5062
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Guggenheim Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $7
Guggenheim analyst Yatin Suneja initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $7.
03-24 19:39
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Immunic to Participate in Investor Conferences in March
NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestina...
03-03 19:30
Twilio To Rally More Than 32%? Here Are 10 Top Analyst Forecasts For Monday
Wall Street analysts changed outlook on top names: BTIG cut CRWD PT, Piper Sandler cut BSY PT, RBC Capital cut AARD PT, TD Cowen raised TWLO PT, Morgan Stanley raised FLYW PT, Stifel boosted QSR PT, Morgan Stanley increased ZION PT, HC Wainwright cut IMUX PT
03-02 20:57
HC Wainwright & Co. Maintains Buy on Immunic, Lowers Price Target to $5
HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $5.
03-02 19:36
Immunic Q4 EPS $(0.04) Beats $(0.09) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 53.49 percent. This is a 84 percent increase over losses of $(0.25) per share from the same
02-26 21:44
IMUX FY 2025 Other Income (Expense) Swings to USD 5.0 million from (USD 1.0 million)
IMUX FY 2025 Other Income (Expense) Swings to USD 5.0 million from (USD 1.0 million) Immunic said its FY 2025 net loss was about USD 97.2 million, or USD 0.62 per basic and diluted share, compared with a net loss of about USD 100.5 million a year earlier. FY 2025 R&D expenses were USD 82.0 million a
02-26 19:30
Why Is Immunic Stock Soaring Friday?
Immunic stock surges on oversubscribed private placement raising $400 million to accelerate commercialization.
02-14 02:55
Immunic Stock Jumps After Pricing $400 Million Private Placement
Immunic Inc (NASDAQ:IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.
02-14 00:25
